<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en" dir="ltr">
  <head>
    <meta http-equiv="Content-Type" content="text/html; charset=UTF-8" />
    		<meta name="keywords" content="Amiodarone,Amiodarone.png,Antiarrhythmic agents,Antiarrhythmic agents,1961,1970s,1980s,1985,ATC code C01,ATC code C07,ATC code C08" />
		<link rel="shortcut icon" href="/favicon.ico" />
		<link rel="search" type="application/opensearchdescription+xml" href="/w/opensearch_desc.php" title="Wikipedia (English)" />
		<link rel="copyright" href="../../../COPYING.html" />
    <title>Amiodarone - Wikipedia, the free encyclopedia</title>
    <style type="text/css">/*<![CDATA[*/ @import "../../../skins/htmldump/main.css"; /*]]>*/</style>
    <link rel="stylesheet" type="text/css" media="print" href="../../../skins/common/commonPrint.css" />
    <!--[if lt IE 5.5000]><style type="text/css">@import "../../../skins/monobook/IE50Fixes.css";</style><![endif]-->
    <!--[if IE 5.5000]><style type="text/css">@import "../../../skins/monobook/IE55Fixes.css";</style><![endif]-->
    <!--[if IE 6]><style type="text/css">@import "../../../skins/monobook/IE60Fixes.css";</style><![endif]-->
    <!--[if IE]><script type="text/javascript" src="../../../skins/common/IEFixes.js"></script>
    <meta http-equiv="imagetoolbar" content="no" /><![endif]-->
    <script type="text/javascript" src="../../../skins/common/wikibits.js"></script>
    <script type="text/javascript" src="../../../skins/htmldump/md5.js"></script>
    <script type="text/javascript" src="../../../skins/htmldump/utf8.js"></script>
    <script type="text/javascript" src="../../../skins/htmldump/lookup.js"></script>
    <script type="text/javascript" src="../../../raw/gen.js"></script>        <style type="text/css">/*<![CDATA[*/
@import "../../../raw/MediaWiki%7ECommon.css";
@import "../../../raw/MediaWiki%7EMonobook.css";
@import "../../../raw/gen.css";
/*]]>*/</style>          </head>
  <body
    class="ns-0">
    <div id="globalWrapper">
      <div id="column-content">
	<div id="content">
	  <a name="top" id="contentTop"></a>
	        <h1 class="firstHeading">Amiodarone</h1>
	  <div id="bodyContent">
	    <h3 id="siteSub">From Wikipedia, the free encyclopedia</h3>
	    <div id="contentSub"></div>
	    	    <div class="usermessage">You have <a href="../../../1/2/7/User_talk%7E127.0.0.1.html" title="User talk:127.0.0.1">new messages</a> (<a href="../../../1/2/7/User_talk%7E127.0.0.1.html" title="User talk:127.0.0.1">last change</a>).</div>	    <!-- start content -->
	    <table id="drugInfoBox" style="float: right; clear: right; margin: 0 0 0.5em 1em; background: #ffffff;" class="toccolours" border="0" cellpadding="1" align="right" width="280">
<tr>
<td align="center" colspan="2"><a href="../../../a/m/i/Image%7EAmiodarone.png_630c.html" class="image" title=""><img src="../../../upload/shared/thumb/6/6f/Amiodarone.png/220px-Amiodarone.png" alt="" width="220" height="167" longdesc="../../../a/m/i/Image%7EAmiodarone.png_630c.html" /></a></td>
</tr>
<tr>
<td align="center" colspan="2">
<div style="font-size:medium; line-height:167%;">Amiodarone</div>
</td>
</tr>
<tr>
<td colspan="2" bgcolor="#DDDDDD"><b>Systematic (<a href="../../../i/n/t/International_Union_of_Pure_and_Applied_Chemistry_nomenclature_efd4.html" title="International Union of Pure and Applied Chemistry nomenclature">IUPAC</a>) name</b></td>
</tr>
<tr>
<td bgcolor="#EEEEEE" style="text-align: center; vertical-align: top;" colspan="2"><span style="font-size:11px">(2-butylbenzofuran-3-yl)- [4-(2-diethylaminoethoxy)- 3,5-diiodo-phenyl]- methanone (as the hydrochloride salt)</span></td>
</tr>
<tr>
<td colspan="2" bgcolor="#DDDDDD"><b>Identifiers</b></td>
</tr>
<tr>
<td bgcolor="#DDEEFF" width="90"><a href="../../../c/a/s/CAS_registry_number_4b20.html" title="CAS registry number">CAS number</a></td>
<td bgcolor="#EEEEEE"><span class="reflink plainlinksneverexpand"><a href="http://www.nlm.nih.gov/cgi/mesh/2006/MB_cgi?term=1951-25-3&amp;rn=1" class="external text" title="http://www.nlm.nih.gov/cgi/mesh/2006/MB_cgi?term=1951-25-3&amp;rn=1" rel="nofollow">1951-25-3</a></span></td>
</tr>
<tr>
<td bgcolor="#DDEEFF"><a href="../../../a/n/a/Anatomical_Therapeutic_Chemical_Classification_System_186e.html" title="Anatomical Therapeutic Chemical Classification System">ATC code</a></td>
<td bgcolor="#EEEEEE"><a href="../../../a/t/c/ATC_code_C01_98cd.html" title="ATC code C01">C01</a><span class="reflink plainlinksneverexpand"><a href="http://www.whocc.no/atcddd/indexdatabase/index.php?query=C01BD01" class="external text" title="http://www.whocc.no/atcddd/indexdatabase/index.php?query=C01BD01" rel="nofollow">BD01</a></span></td>
</tr>
<tr>
<td bgcolor="#DDEEFF"><a href="../../../p/u/b/PubChem_a50b.html" title="PubChem">PubChem</a></td>
<td bgcolor="#EEEEEE"><span class="reflink plainlinksneverexpand"><a href="http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=2157" class="external text" title="http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=2157" rel="nofollow">2157</a></span></td>
</tr>
<tr>
<td bgcolor="#DDEEFF"><a href="../../../d/r/u/DrugBank_2050.html" title="DrugBank">DrugBank</a></td>
<td bgcolor="#EEEEEE"><span class="reflink plainlinksneverexpand"><a href="http://redpoll.pharmacy.ualberta.ca/drugbank/cgi-bin/getCard.cgi?CARD=APRD00288" class="external text" title="http://redpoll.pharmacy.ualberta.ca/drugbank/cgi-bin/getCard.cgi?CARD=APRD00288" rel="nofollow">APRD00288</a></span></td>
</tr>
<tr>
<td colspan="2" bgcolor="#DDDDDD"><b>Chemical data</b></td>
</tr>
<tr>
<td bgcolor="#DDEEFF"><a href="../../../c/h/e/Chemical_formula.html" title="Chemical formula">Formula</a></td>
<td bgcolor="#EEEEEE"><a href="../../../c/a/r/Carbon.html" title="Carbon"><span style="color: rgb(000,000,000); font-weight: bold;">C</span></a><sub>25</sub><a href="../../../h/y/d/Hydrogen.html" title="Hydrogen"><span style="color: rgb(154,154,154); font-weight: bold;">H</span></a><sub>29</sub><a href="../../../i/o/d/Iodine.html" title="Iodine"><span style="color: rgb(148,022,148); font-weight: bold;">I</span></a><sub>2</sub><a href="../../../n/i/t/Nitrogen.html" title="Nitrogen"><span style="color: rgb(000,000,255); font-weight: bold;">N</span></a><a href="../../../o/x/y/Oxygen.html" title="Oxygen"><span style="color: rgb(232,070,070); font-weight: bold;">O</span></a><sub>3</sub><sup>&#160;</sup></td>
</tr>
<tr>
<td bgcolor="#DDEEFF"><a href="../../../m/o/l/Molecular_mass.html" title="Molecular mass">Mol. mass</a></td>
<td bgcolor="#EEEEEE">681.78 g/mol</td>
</tr>
<tr>
<td colspan="2" bgcolor="#DDDDDD"><b>Pharmacokinetic data</b></td>
</tr>
<tr>
<td bgcolor="#DDEEFF" style="vertical-align: top;"><a href="../../../b/i/o/Bioavailability.html" title="Bioavailability">Bioavailability</a></td>
<td bgcolor="#EEEEEE">20 - 55%</td>
</tr>
<tr>
<td bgcolor="#DDEEFF" style="vertical-align: top;"><a href="../../../d/r/u/Drug_metabolism.html" title="Drug metabolism">Metabolism</a></td>
<td bgcolor="#EEEEEE"><a href="../../../l/i/v/Liver.html" title="Liver">Liver</a></td>
</tr>
<tr>
<td bgcolor="#DDEEFF" style="vertical-align: top;"><a href="../../../b/i/o/Biological_half-life.html" title="Biological half-life">Half life</a></td>
<td bgcolor="#EEEEEE">58 days (range 15-142 days)</td>
</tr>
<tr>
<td bgcolor="#DDEEFF" style="vertical-align: top;"><a href="../../../e/x/c/Excretion.html" title="Excretion">Excretion</a></td>
<td bgcolor="#EEEEEE"><a href="../../../e/p/i/Epithelial_cell.html" title="Epithelial cell">Epithelial cells</a></td>
</tr>
<tr>
<td colspan="2" bgcolor="#DDDDDD"><b>Therapeutic considerations</b></td>
</tr>
<tr>
<td bgcolor="#DDEEFF" style="vertical-align: top;"><a href="../../../p/r/e/Pregnancy_category.html" title="Pregnancy category">Pregnancy cat.</a></td>
<td bgcolor="#EEEEEE">
<p>D<small>(<a href="../../../u/n/i/United_States_09d4.html" title="United States">US</a>)</small></p>
</td>
</tr>
<tr>
<td bgcolor="#DDEEFF" style="vertical-align: top;"><a href="../../../r/e/g/Regulation_of_therapeutic_goods.html" title="Regulation of therapeutic goods">Legal status</a></td>
<td bgcolor="#EEEEEE">
<p><span class="Unicode">â„ž</span> P<small>rescription only</small></p>
</td>
</tr>
<tr>
<td bgcolor="#DDEEFF" style="vertical-align: top;"><a href="../../../r/o/u/Route_of_administration.html" title="Route of administration">Routes</a></td>
<td bgcolor="#EEEEEE"><a href="http://en.wiktionary.org/wiki/oral" class="extiw" title="wiktionary:oral">oral</a> or <a href="../../../i/n/t/Intravenous.html" title="Intravenous">intravenous</a></td>
</tr>
</table>
<p><b>Amiodarone</b> belongs to a class of drugs called Vaughan-Williams Class III <a href="../../../a/n/t/Antiarrhythmic_agents.html" title="Antiarrhythmic agents">antiarrhythmic agent</a>. It is used in the treatment of a wide range of cardiac tachyarrhythmias, including both ventricular and supraventricular (atrial) arrhythmias.</p>
<table id="toc" class="toc" summary="Contents">
<tr>
<td>
<div id="toctitle">
<h2>Contents</h2>
</div>
<ul>
<li class="toclevel-1"><a href="#History"><span class="tocnumber">1</span> <span class="toctext">History</span></a></li>
<li class="toclevel-1"><a href="#Dosing"><span class="tocnumber">2</span> <span class="toctext">Dosing</span></a></li>
<li class="toclevel-1"><a href="#Mechanism_of_action"><span class="tocnumber">3</span> <span class="toctext">Mechanism of action</span></a></li>
<li class="toclevel-1"><a href="#Indications_for_use"><span class="tocnumber">4</span> <span class="toctext">Indications for use</span></a>
<ul>
<li class="toclevel-2"><a href="#Ventricular_fibrillation"><span class="tocnumber">4.1</span> <span class="toctext">Ventricular fibrillation</span></a></li>
<li class="toclevel-2"><a href="#Ventricular_tachycardia"><span class="tocnumber">4.2</span> <span class="toctext">Ventricular tachycardia</span></a></li>
<li class="toclevel-2"><a href="#Atrial_fibrillation"><span class="tocnumber">4.3</span> <span class="toctext">Atrial fibrillation</span></a></li>
</ul>
</li>
<li class="toclevel-1"><a href="#Contraindications"><span class="tocnumber">5</span> <span class="toctext">Contraindications</span></a></li>
<li class="toclevel-1"><a href="#Metabolism"><span class="tocnumber">6</span> <span class="toctext">Metabolism</span></a>
<ul>
<li class="toclevel-2"><a href="#Interactions_with_other_drugs"><span class="tocnumber">6.1</span> <span class="toctext">Interactions with other drugs</span></a></li>
</ul>
</li>
<li class="toclevel-1"><a href="#Excretion"><span class="tocnumber">7</span> <span class="toctext">Excretion</span></a></li>
<li class="toclevel-1"><a href="#Side_effects"><span class="tocnumber">8</span> <span class="toctext">Side effects</span></a>
<ul>
<li class="toclevel-2"><a href="#Thyroid"><span class="tocnumber">8.1</span> <span class="toctext">Thyroid</span></a></li>
<li class="toclevel-2"><a href="#Eye"><span class="tocnumber">8.2</span> <span class="toctext">Eye</span></a></li>
<li class="toclevel-2"><a href="#Gastrointestinal_system"><span class="tocnumber">8.3</span> <span class="toctext">Gastrointestinal system</span></a></li>
<li class="toclevel-2"><a href="#Skin"><span class="tocnumber">8.4</span> <span class="toctext">Skin</span></a></li>
<li class="toclevel-2"><a href="#Lung"><span class="tocnumber">8.5</span> <span class="toctext">Lung</span></a></li>
</ul>
</li>
<li class="toclevel-1"><a href="#See_also"><span class="tocnumber">9</span> <span class="toctext">See also</span></a></li>
<li class="toclevel-1"><a href="#References"><span class="tocnumber">10</span> <span class="toctext">References</span></a></li>
<li class="toclevel-1"><a href="#External_links"><span class="tocnumber">11</span> <span class="toctext">External links</span></a></li>
</ul>
</td>
</tr>
</table>
<p><script type="text/javascript">
//<![CDATA[
 if (window.showTocToggle) { var tocShowText = "show"; var tocHideText = "hide"; showTocToggle(); } 
//]]>
</script><a name="History" id="History"></a></p>
<h2><span class="editsection">[<a href="../../../a/m/i/Amiodarone.html" title="Edit section: History">edit</a>]</span> <span class="mw-headline">History</span></h2>
<p>Amiodarone was initially developed in <a href="../../../1/9/6/1961.html" title="1961">1961</a> in <a href="../../../b/e/l/Belgium.html" title="Belgium">Belgium</a> as a treatment for <a href="../../../a/n/g/Angina.html" title="Angina">angina</a>. It was widely used throughout <a href="../../../e/u/r/Europe.html" title="Europe">Europe</a> as an anti-anginal medication, and was soon found to suppress arrhythmias.</p>
<p>Dr. Bramah Singh determined that amiodarone and <a href="../../../s/o/t/Sotalol.html" title="Sotalol">sotalol</a> belonged to a new class of antiarrhythmic agents (what would become the class III antiarrhythmic agents). Today their mechanism of action is unknown. It is thought to involve prolonging the action potential duration, prolonging the refractory period, or interacting with K+ channels. Based on this, the <a href="../../../a/r/g/Argentina.html" title="Argentina">Argentinian</a> physician Dr. Mauricio Rosenbaum began using amiodarone to treat his patients who suffered from supraventricular and ventricular arrhythmias, with impressive results. Based on papers written by Dr. Rosenbaum, physicians in the <a href="../../../u/n/i/United_States_09d4.html" title="United States">United States</a> began prescribing amiodarone to their patients with potentially life-threatening arrhythmias in the late <a href="../../../1/9/7/1970s.html" title="1970s">1970s</a>. By that time, amiodarone was commonly prescribed throughout Europe for the treatment of arrhythmias. Because amiodarone was not approved by the <a href="../../../f/o/o/Food_and_Drug_Administration_b75c.html" title="Food and Drug Administration">Food and Drug Administration</a> for use in the United States at the time, physicians were forced to directly obtain amiodarone from pharmaceutical companies in <a href="../../../c/a/n/Canada.html" title="Canada">Canada</a> and <a href="../../../e/u/r/Europe.html" title="Europe">Europe</a>.</p>
<p>The FDA was reluctant to officially approve the use of amiodarone, since initial reports had shown increased incidence of serious pulmonary side-effects of the drug. In the mid <a href="../../../1/9/8/1980s.html" title="1980s">1980s</a>, the European pharmaceutical companies began putting pressure on the FDA to approve amiodarone by threatening to cut the supply to the American physicians if it was not approved. In December of <a href="../../../1/9/8/1985.html" title="1985">1985</a>, amiodarone was approved by the FDA for the treatment of arrhythmias. This makes amiodarone one of the few drugs approved by the FDA without rigorous randomized clinical trials.</p>
<p><a name="Dosing" id="Dosing"></a></p>
<h2><span class="editsection">[<a href="../../../a/m/i/Amiodarone.html" title="Edit section: Dosing">edit</a>]</span> <span class="mw-headline">Dosing</span></h2>
<p>Amiodarone is available in oral and intravenous formulations.</p>
<p>Orally, it is available under the trade names <b>Pacerone<sup>Â®</sup></b> (produced by Upsher-Smith Laboratories, Inc.) and <b>Cordarone<sup>Â®</sup></b> (produced by Wyeth-Ayerst Laboratories) in 200<a href="../../../m/i/l/Milligram.html" title="Milligram">mg</a> and 400 mg tablets; It is also available under the trade name <b>Aratac<sup>Â®</sup></b> in 100 mg and 200 mg tablets in Australia and New Zealand.</p>
<p>It is also available in intravenous ampules and vials, typically in 150 mg increments.</p>
<p>The dose of amiodarone administered is tailored to the individual and the dysrhythmia that is being treated. When administered orally, the <a href="../../../b/i/o/Bioavailability.html" title="Bioavailability">bioavailability</a> of amiodarone is quite variable. Absorption ranges from 22 to 95%, with better absorption when it is given with food.<sup id="_ref-0" class="reference"><a href="#_note-0" title="">[1]</a></sup></p>
<p>Amiodarone is fat-soluble, and tends to concentrate in tissues including fat, muscle, liver, lungs, and skin. This confers a high <a href="../../../v/o/l/Volume_of_distribution.html" title="Volume of distribution">volume of distribution</a> (5000 liters in a 70 kg adult) and a long half-life. Due to the long half-life of amiodarone, oral loading typically takes days to weeks.</p>
<p>An oral loading dose is typically a total of 10 grams, divided over one to two weeks. Once an individual is loaded, a typical maintenance dose of amiodarone is 100 or 200 mg either once or twice daily.</p>
<p>An intravenous loading dose is typically 300 mg in 20-30cc D5W for cardiac arrest. The loading infusion for dysrhythmias is typically 150 mg in a 100cc bag of D5W given over 10 minutes. Both can be followed by a 360 mg slow infusion over 6 hours then a maintenance infusion of 540 mg over 18 hours.</p>
<p><a name="Mechanism_of_action" id="Mechanism_of_action"></a></p>
<h2><span class="editsection">[<a href="../../../a/m/i/Amiodarone.html" title="Edit section: Mechanism of action">edit</a>]</span> <span class="mw-headline">Mechanism of action</span></h2>
<p>Amiodarone is categorized as a class III <a href="../../../a/n/t/Antiarrhythmic_agents.html" title="Antiarrhythmic agents">antiarrhythmic agent</a>, and prolongs phase 3 of the <a href="../../../c/a/r/Cardiac_action_potential.html" title="Cardiac action potential">cardiac action potential</a>. It has numerous other effects however, including actions that are similar to those of antiarrhythmic classes Ia, II, and IV.</p>
<p>Amiodarone shows <a href="../../../b/e/t/Beta_blocker.html" title="Beta blocker">beta blocker</a>-like and <a href="../../../c/a/l/Calcium_channel_blocker.html" title="Calcium channel blocker">calcium channel blocker</a>-like actions on the <a href="../../../s/a/_/SA_node_b9a0.html" title="SA node">SA</a> and <a href="../../../a/v/_/AV_node_985a.html" title="AV node">AV nodes</a>, increases the refractory period via sodium- and potassium-channel effects, and slows intra-cardiac conduction of the <a href="../../../c/a/r/Cardiac_action_potential.html" title="Cardiac action potential">cardiac action potential</a>, via sodium-channel effects.</p>
<p><a name="Indications_for_use" id="Indications_for_use"></a></p>
<h2><span class="editsection">[<a href="../../../a/m/i/Amiodarone.html" title="Edit section: Indications for use">edit</a>]</span> <span class="mw-headline">Indications for use</span></h2>
<p>Because amiodarone has a low incidence of pro-arrhythmic effects, it has been used both in the treatment of acute life-threatening arrhythmias as well as the chronic suppression of arrhythmias. It is useful both in supraventricular arrhythmias and ventricular arrhythmias.</p>
<p><a name="Ventricular_fibrillation" id="Ventricular_fibrillation"></a></p>
<h3><span class="editsection">[<a href="../../../a/m/i/Amiodarone.html" title="Edit section: Ventricular fibrillation">edit</a>]</span> <span class="mw-headline">Ventricular fibrillation</span></h3>
<p>The treatment of choice for <a href="../../../v/e/n/Ventricular_fibrillation.html" title="Ventricular fibrillation">ventricular fibrillation</a> (VF) is electrical defibrillation. However, amiodarone can be useful in shock-refractory VF. In the ARREST trial, amiodarone was shown to improve survival to <a href="../../../h/o/s/Hospital.html" title="Hospital">hospital</a> admission (when compared to <a href="../../../p/l/a/Placebo.html" title="Placebo">placebo</a>) in individuals who suffer <a href="../../../c/a/r/Cardiac_arrest.html" title="Cardiac arrest">cardiac arrest</a> with shock-refractory VF.<sup id="_ref-1" class="reference"><a href="#_note-1" title="">[2]</a></sup> It is on the basis of this study that the guidelines created by the <a href="../../../a/m/e/American_Heart_Association_032c.html" title="American Heart Association">American Heart Association</a> for the treatment of VF include amiodarone as a second line agent (after <a href="../../../e/p/i/Epinephrine.html" title="Epinephrine">epinephrine</a> or <a href="../../../v/a/s/Vasopressin.html" title="Vasopressin">vasopressin</a>). ARREST was not adequately powered to demonstrate survival to hospital discharge.</p>
<p><a name="Ventricular_tachycardia" id="Ventricular_tachycardia"></a></p>
<h3><span class="editsection">[<a href="../../../a/m/i/Amiodarone.html" title="Edit section: Ventricular tachycardia">edit</a>]</span> <span class="mw-headline">Ventricular tachycardia</span></h3>
<p>Amiodarone may be used in the treatment of ventricular tachycardia in certain instances. Individuals with hemodynamically <i>unstable</i> ventricular tachycardia <i>should not</i> initially receive amiodarone. These individuals should be <a href="../../../c/a/r/Cardioversion.html" title="Cardioversion">cardioverted</a> out of their unstable rhythm.</p>
<p>Amiodarone can be used in individuals with hemodynamically stable ventricular tachycardia. In these cases, amiodarone can be used regardless of the individual's underlying heart function and the type of ventricular tachycardia; it can be used in individuals with monomorphic ventricular tachycardia as well as individuals with <a href="../../../p/o/l/Polymorphic_ventricular_tachycardia.html" title="Polymorphic ventricular tachycardia">polymorphic ventricular tachycardia</a>. The dose of amiodarone is 150 <a href="../../../m/i/l/Milligram.html" title="Milligram">mg</a> <a href="../../../i/n/t/Intravenous.html" title="Intravenous">IV</a> administered over 10 minutes.</p>
<p><a name="Atrial_fibrillation" id="Atrial_fibrillation"></a></p>
<h3><span class="editsection">[<a href="../../../a/m/i/Amiodarone.html" title="Edit section: Atrial fibrillation">edit</a>]</span> <span class="mw-headline">Atrial fibrillation</span></h3>
<p>Individuals who have undergone <a href="../../../c/o/r/Coronary_artery_bypass_surgery.html" title="Coronary artery bypass surgery">open heart surgery</a> are at an increased risk of developing <a href="../../../a/t/r/Atrial_fibrillation.html" title="Atrial fibrillation">atrial fibrillation</a> (or AF) in the first few days post-procedure. In the ARCH trial, <a href="../../../i/n/t/Intravenous.html" title="Intravenous">intravenous</a> amiodarone (2 <a href="../../../g/r/a/Gram.html" title="Gram">grams</a> administered over 2 days) has been shown to reduce the incidence of atrial fibrillation after open heart surgery when compared to placebo.<sup id="_ref-2" class="reference"><a href="#_note-2" title="">[3]</a></sup> However, clinical studies have failed to demonstrate long-term efficacy and have shown potentially fatal side effects such as pulmonary toxicities. While Amiodarone is not approved for AF by the FDA, it is a commonly prescribed off-label treatment due to the lack of efficacious treatment alternatives.</p>
<p>So called acute onset atrial fibrillation defined by the the North American Society of Pacing and Electrophysiology (NASPE)in 2003 responds well to short duration treatment with amiodarone. This has been demonstrated in seventeen randomised controlled trials, of which five included a placebo arm. The incidence of severe side effects in this group is low. The benefit of amiodarone in the treatment of atrial fibrillation in the critical care population has yet to be determined but it may prove to be the agent of choice where the patient is haemodynamically unstable and unsuitable for DC cardioversion. It is recommended in such a role by the UK government's <a href="../../../n/a/t/National_Institute_for_Health_and_Clinical_Excellence_6317.html" title="National Institute for Health and Clinical Excellence">National Institute for Health and Clinical Excellence</a> (NICE).</p>
<p><a name="Contraindications" id="Contraindications"></a></p>
<h2><span class="editsection">[<a href="../../../a/m/i/Amiodarone.html" title="Edit section: Contraindications">edit</a>]</span> <span class="mw-headline">Contraindications</span></h2>
<p>The only absolute contraindications to the administration of amiodarone is allergic reaction (ie: <a href="../../../a/n/a/Anaphylaxis.html" title="Anaphylaxis">anaphylaxis</a>) to the compound. However, because of the wide spectrum of the mechanism of action of amiodarone and the numerous side effects possible, there are a number of groups for which care should be taken when administering the drug.</p>
<p>Individuals who are <a href="../../../p/r/e/Pregnant.html" title="Pregnant">pregnant</a> or may become pregnant are strongly advised to not take amiodarone. Since amiodarone can be expressed in breast milk, women taking amiodarone are advised to stop nursing.</p>
<p>It is contraindicated in individuals with <a href="../../../s/i/n/Sinus_node.html" title="Sinus node">sinus nodal</a> bradycardia, <a href="../../../a/t/r/Atrioventricular_node.html" title="Atrioventricular node">atrioventricular</a> block, and second or third degree heart block who do not have an <a href="../../../a/r/t/Artificial_pacemaker.html" title="Artificial pacemaker">artificial pacemaker</a>.</p>
<p>Individuals with baseline depressed lung function should be monitored closely if amiodarone therapy is to be initiated.</p>
<p>The injection should not be given to neonates, because the benzyl alcohol it contains may cause the fatal "gasping syndrome".</p>
<p><a name="Metabolism" id="Metabolism"></a></p>
<h2><span class="editsection">[<a href="../../../a/m/i/Amiodarone.html" title="Edit section: Metabolism">edit</a>]</span> <span class="mw-headline">Metabolism</span></h2>
<p>Amiodarone is extensively metabolized in the liver, and can affect the metabolism of numerous other <a href="../../../m/e/d/Medication.html" title="Medication">drugs</a>. The major metabolite of amiodarone is desethylamiodarone (DEA), which also has antiarrhythmic properties. The metabolism of amiodarone is inhibited by <a href="../../../g/r/a/Grapefruit.html" title="Grapefruit">grapefruit</a> juice, leading to elevated <a href="../../../b/l/o/Blood_plasma.html" title="Blood plasma">serum</a> levels of amiodarone.</p>
<p><a name="Interactions_with_other_drugs" id="Interactions_with_other_drugs"></a></p>
<h3><span class="editsection">[<a href="../../../a/m/i/Amiodarone.html" title="Edit section: Interactions with other drugs">edit</a>]</span> <span class="mw-headline">Interactions with other drugs</span></h3>
<p>The <a href="../../../p/h/a/Pharmacokinetics.html" title="Pharmacokinetics">pharmacokinetics</a> of numerous <a href="../../../m/e/d/Medication.html" title="Medication">drugs</a>, including many that are commonly administered to individuals with <a href="../../../h/e/a/Heart.html" title="Heart">heart</a> disease, are affected by amiodarone. Particularly, doses of <a href="../../../d/i/g/Digoxin.html" title="Digoxin">digoxin</a> should be halved in individuals taking amiodarone.</p>
<p>Amiodarone potentiates the action of <a href="../../../w/a/r/Warfarin.html" title="Warfarin">warfarin</a>. Individuals taking both of these medications should have their warfarin dose halved and their anticoagulation status (measured as <a href="../../../p/r/o/Prothrombin_time.html" title="Prothrombin time">prothrombin time</a> (PT) and <a href="../../../i/n/t/International_normalized_ratio.html" title="International normalized ratio">international normalized ratio</a> (INR)) measured more frequently. The effect of amiodarone in the warfarin concentration can be as early as a few days after initiation of treatment, or can be delayed a few weeks.</p>
<p>Amiodarone inhibits the action of the <a href="../../../c/y/t/Cytochrome_P450_af36.html" title="Cytochrome P450">cytochrome P450</a> <a href="../../../i/s/o/Isozyme.html" title="Isozyme">isozyme</a> family. This reduces the clearance of many drugs, including the following: -</p>
<ul>
<li><a href="../../../c/i/c/Ciclosporin.html" title="Ciclosporin">Ciclosporin</a></li>
<li><a href="../../../d/i/g/Digoxin.html" title="Digoxin">Digoxin</a></li>
<li><a href="../../../f/l/e/Flecainide.html" title="Flecainide">Flecainide</a></li>
<li><a href="../../../p/r/o/Procainamide.html" title="Procainamide">Procainamide</a></li>
<li><a href="../../../q/u/i/Quinidine.html" title="Quinidine">Quinidine</a></li>
<li><a href="../../../s/i/l/Sildenafil.html" title="Sildenafil">Sildenafil</a></li>
<li><a href="../../../s/i/m/Simvastatin.html" title="Simvastatin">Simvastatin</a></li>
<li><a href="../../../t/h/e/Theophylline.html" title="Theophylline">Theophylline</a></li>
<li><a href="../../../w/a/r/Warfarin.html" title="Warfarin">Warfarin</a></li>
</ul>
<p><a name="Excretion" id="Excretion"></a></p>
<h2><span class="editsection">[<a href="../../../a/m/i/Amiodarone.html" title="Edit section: Excretion">edit</a>]</span> <span class="mw-headline">Excretion</span></h2>
<p>Unlike most other <a href="../../../m/e/d/Medication.html" title="Medication">drugs</a>, which are excreted via the <a href="../../../u/r/i/Urine.html" title="Urine">urine</a> or <a href="../../../f/e/c/Feces.html" title="Feces">feces</a>, amiodarone is excreted via shedding of <a href="../../../e/p/i/Epithelial_cell.html" title="Epithelial cell">epithelial cells</a>. This includes loss of skin cells and loss of the cells of the lining of the <a href="../../../g/a/s/Gastrointestinal_system.html" title="Gastrointestinal system">gastrointestinal system</a>. While the human body sheds millions of cells a day, the amount of amiodarone lost per day is small, giving a long <a href="../../../h/a/l/Half_life.html" title="Half life">half life</a> (13 to 103 days). Therefore, if an individual was taking amiodarone on a chronic basis, if it is stopped it will remain in the system for months.</p>
<p><a name="Side_effects" id="Side_effects"></a></p>
<h2><span class="editsection">[<a href="../../../a/m/i/Amiodarone.html" title="Edit section: Side effects">edit</a>]</span> <span class="mw-headline">Side effects</span></h2>
<p>Amiodarone has numerous side effects. Most individuals administered amiodarone on a chronic basis will experience at least one side effect.</p>
<p><a name="Thyroid" id="Thyroid"></a></p>
<h3><span class="editsection">[<a href="../../../a/m/i/Amiodarone.html" title="Edit section: Thyroid">edit</a>]</span> <span class="mw-headline">Thyroid</span></h3>
<p>Due to the iodine content of the agent (37.3% by weight), abnormalities in <a href="../../../t/h/y/Thyroid.html" title="Thyroid">thyroid</a> function are common. Amiodarone is structurally similar to <a href="../../../t/h/y/Thyroxine.html" title="Thyroxine">thyroxine</a> (a thyroid hormone), which contributes to the effects of amiodarone on thyroid function. The incidence of <a href="../../../h/y/p/Hypothyroidism.html" title="Hypothyroidism">hypothyroidism</a> is about 6%, while the incidence of <a href="../../../h/y/p/Hyperthyroidism.html" title="Hyperthyroidism">hyperthyroidism</a> is about 2%. They are called <a href="../../../w/o/l/Wolff-Chaikoff_effect_3b74.html" title="Wolff-Chaikoff effect">Wolff-Chaikoff effect</a> and <a href="../../../j/o/d/Jodbasedow.html" title="Jodbasedow">Jodbasedow</a> effect separately.</p>
<p>Measurement of free <a href="../../../t/h/y/Thyroxine.html" title="Thyroxine">thyroxine</a> (FT4) alone may be unreliable and <a href="../../../t/h/y/Thyroid-stimulating_hormone.html" title="Thyroid-stimulating hormone">thyroid-stimulating hormone</a> (TSH) should therefore also be checked every 6 months.<sup id="_ref-3" class="reference"><a href="#_note-3" title="">[4]</a></sup></p>
<p>Thyroid uptake measurements (I-123 or I-131), which are used to differentiate causes of hyperthyroidism, are generally unreliable in patients who have been taking amiodarone. Because of the high iodine content of amiodarone, the thyroid gland is effectively saturated, thus preventing further uptake of isotopes of iodine. However, the radioactive iodine uptake (nuclear thyroid uptake test) may still be helpful in the diagnosis and management of amiodarone-induced hyperthyroidism.</p>
<p><a name="Eye" id="Eye"></a></p>
<h3><span class="editsection">[<a href="../../../a/m/i/Amiodarone.html" title="Edit section: Eye">edit</a>]</span> <span class="mw-headline">Eye</span></h3>
<p><a href="../../../c/o/r/Cornea.html" title="Cornea">Corneal</a> micro-deposits (Corneal verticillata, also called vortex keratopathy) are almost universally present (over 90%) in individuals taking amiodarone for at least 6 months. These deposits typically do not cause any symptoms. About 1 in 10 individuals may complain of a blueish halo. Optic neuropathy occurs in 1-2% of people and is not dosage dependent. Bilateral optic disk swelling and mild and reversible visual field defects can also occur.</p>
<p><a name="Gastrointestinal_system" id="Gastrointestinal_system"></a></p>
<h3><span class="editsection">[<a href="../../../a/m/i/Amiodarone.html" title="Edit section: Gastrointestinal system">edit</a>]</span> <span class="mw-headline">Gastrointestinal system</span></h3>
<p>Liver toxicity due to amiodarone is quite rare. A drug-induced <a href="../../../h/e/p/Hepatitis.html" title="Hepatitis">hepatitis</a> (inflammation of the liver) may occur and is sometimes reversible by lowering the dose.</p>
<p><a name="Skin" id="Skin"></a></p>
<h3><span class="editsection">[<a href="../../../a/m/i/Amiodarone.html" title="Edit section: Skin">edit</a>]</span> <span class="mw-headline">Skin</span></h3>
<p>Long-term administration of amiodarone is associated with a blue-grey discoloration of the skin, "smurf syndrome." This is more commonly seen in individuals with lighter skin tones. The discoloration may revert upon cessation of the drug. However, the skin color may not return completely to normal.</p>
<p>Individuals taking amiodarone may become more sensitive to the harmful effects of <a href="../../../u/l/t/Ultraviolet.html" title="Ultraviolet">UV-A</a> light. Taking sunblock that also blocks UV-A rays appears to prevent this side effect.</p>
<p><a name="Lung" id="Lung"></a></p>
<h3><span class="editsection">[<a href="../../../a/m/i/Amiodarone.html" title="Edit section: Lung">edit</a>]</span> <span class="mw-headline">Lung</span></h3>
<p>The most serious reaction that is due to amiodarone is <a href="../../../i/n/t/Interstitial_lung_disease.html" title="Interstitial lung disease">interstitial lung disease</a>. The incidence of pulmonary fibrosis is not dose related. Some individuals were noted to develop pulmonary fibrosis after a week of treatment, while others did not develop it after years of continuous use. There are no known factors that increase the incidence of amiodarone-induced pulmonary fibrosis in a particular individual. Common practice is to avoid the agent if possible in individuals with decreased lung function.</p>
<p>The most specific test of pulmonary toxicity due to amiodarone is a dramatically decreased <a href="../../../d/l/c/Dlco.html" title="Dlco">DL<sub>CO</sub></a> noted on <a href="../../../p/u/l/Pulmonary_function_test.html" title="Pulmonary function test">pulmonary function testing</a>.</p>
<p><a name="See_also" id="See_also"></a></p>
<h2><span class="editsection">[<a href="../../../a/m/i/Amiodarone.html" title="Edit section: See also">edit</a>]</span> <span class="mw-headline">See also</span></h2>
<ul>
<li><a href="../../../a/d/v/Advanced_cardiac_life_support.html" title="Advanced cardiac life support">Advanced cardiac life support</a> (ACLS)</li>
<li><a href="../../../a/n/t/Antiarrhythmic_agents.html" title="Antiarrhythmic agents">Antiarrhythmic agents</a></li>
<li><a href="../../../a/t/r/Atrial_fibrillation.html" title="Atrial fibrillation">Atrial fibrillation</a></li>
<li><a href="../../../c/a/r/Cardiac_action_potential.html" title="Cardiac action potential">Cardiac action potential</a></li>
<li><a href="../../../d/r/o/Dronedarone.html" title="Dronedarone">Dronedarone</a> (similar drug under investigation)</li>
<li><a href="../../../v/e/n/Ventricular_tachycardia.html" title="Ventricular tachycardia">Ventricular tachycardia</a></li>
</ul>
<p><a name="References" id="References"></a></p>
<h2><span class="editsection">[<a href="../../../a/m/i/Amiodarone.html" title="Edit section: References">edit</a>]</span> <span class="mw-headline">References</span></h2>
<ol class="references">
<li id="_note-0"><b><a href="#_ref-0" title="">^</a></b> Siddoway LA. Amiodarone: Guidelines for Use and Monitoring. American Family Physician Dec. 1, 2003. (<a href="http://www.aafp.org/afp/20031201/2189.html" class="external text" title="http://www.aafp.org/afp/20031201/2189.html" rel="nofollow">Full text</a>)</li>
<li id="_note-1"><b><a href="#_ref-1" title="">^</a></b> Kudenchuk PJ, Cobb LA, Copass MK, Cummins RO, Doherty AM, Fahrenbruch CE, Hallstrom AP, Murray WA, Olsufka M, Walsh T. Amiodarone for resuscitation after out-of-hospital cardiac arrest due to ventricular fibrillation. N Engl J Med. 1999 September 16;341(12):871-8. (<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10486418" class="external text" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10486418" rel="nofollow">Medline abstract</a>)</li>
<li id="_note-2"><b><a href="#_ref-2" title="">^</a></b> Guarnieri T, Nolan S, Gottlieb SO, Dudek A, Lowry DR. Intravenous amiodarone for the prevention of atrial fibrillation after open heart surgery: the Amiodarone Reduction in Coronary Heart (ARCH) trial. J Am Coll Cardiol. 1999 August;34(2):343-7. (<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10440143" class="external text" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10440143" rel="nofollow">Medline abstract</a>)</li>
<li id="_note-3"><b><a href="#_ref-3" title="">^</a></b> <a href="../../../b/r/i/British_National_Formulary_b331.html" title="British National Formulary">British National Formulary</a> guidance on thyroid function monitoring (<a href="http://www.bnf.org/bnf/bnf/49/openat/2417.htm?q=%22amiodarone%22" class="external text" title="http://www.bnf.org/bnf/bnf/49/openat/2417.htm?q=%22amiodarone%22" rel="nofollow">BNF Amiodarone</a>)</li>
</ol>
<p><a name="External_links" id="External_links"></a></p>
<h2><span class="editsection">[<a href="../../../a/m/i/Amiodarone.html" title="Edit section: External links">edit</a>]</span> <span class="mw-headline">External links</span></h2>
<ul>
<li><a href="http://www.medicinenet.com/amiodarone/article.htm" class="external text" title="http://www.medicinenet.com/amiodarone/article.htm" rel="nofollow">Amiodarone (MedicineNet.com)</a></li>
<li><a href="http://www.fpnotebook.com/CV192.htm" class="external text" title="http://www.fpnotebook.com/CV192.htm" rel="nofollow">Amiodarone (FamilyPracticeNotebook.com)</a></li>
<li><a href="http://www.thyroidmanager.org/Chapter13/Ch-13-5.htm" class="external text" title="http://www.thyroidmanager.org/Chapter13/Ch-13-5.htm" rel="nofollow">Iodine-induced thyrotoxicosis</a></li>
<li><a href="http://tiscali.medicdirect.co.uk/tests/default.asp?step=4&amp;pid=1561" class="external text" title="http://tiscali.medicdirect.co.uk/tests/default.asp?step=4&amp;pid=1561" rel="nofollow">Amiodarone (Tiscali.com)</a></li>
<li><a href="http://www.anaesthetist.com/icu/manage/drugs/heart/amiodarone.htm" class="external text" title="http://www.anaesthetist.com/icu/manage/drugs/heart/amiodarone.htm" rel="nofollow">Amiodarone (The WorldWide Intensivist)</a></li>
</ul>
<ul>
<li><a href="../../../c/h/e/Wikipedia%7EChemical_sources_67a4.html" title="Wikipedia:Chemical sources">Links to external chemical sources</a></li>
</ul>
<table class="navbox collapsible" style="margin: auto;">
<tr>
<th colspan="2" style="text-align:center;">
<div style="float:left; text-align:left; width:6em;">
<div class="noprint plainlinksneverexpand" style="background-color:transparent; padding:0; font-weight:normal; font-size:xx-small; color:#000000; white-space:nowrap;"><a href="../../../a/n/t/Template%7EAntiarrhythmic_agents_1eb7.html" title="Template:Antiarrhythmic agents"><span title="View this template">v</span></a>&#160;<span style="font-size:80%;">â€¢</span>&#160;<span style="color: #002bb8;" title="Discussion about this template">d</span>&#160;<span style="font-size:80%;">â€¢</span>&#160;<a href="http://en.wikipedia.org../../../a/n/t/Template%7EAntiarrhythmic_agents_1eb7.html" class="external text" title="http://en.wikipedia.org../../../a/n/t/Template%7EAntiarrhythmic_agents_1eb7.html" rel="nofollow"><span style="color: #002bb8;" title="You can edit this template. Please use the preview button before saving.">e</span></a></div>
</div>
<a href="../../../a/n/t/Antiarrhythmic_agent.html" title="Antiarrhythmic agent">Antiarrhythmic agents</a> (<a href="../../../a/t/c/ATC_code_C01_98cd.html#C01B_Antiarrhythmics.2C_class_I_and_III" title="ATC code C01">C01B</a>)</th>
</tr>
<tr>
<th style="">class Ia</th>
<td style="" colspan="1"><a href="../../../a/j/m/Ajmaline.html" title="Ajmaline">Ajmaline</a>, <a href="../../../d/i/s/Disopyramide.html" title="Disopyramide">Disopyramide</a>, <a href="../../../p/r/a/Prajmaline.html" title="Prajmaline">Prajmaline</a>, <a href="../../../p/r/o/Procainamide.html" title="Procainamide">Procainamide</a>, <a href="../../../q/u/i/Quinidine.html" title="Quinidine">Quinidine</a>, <a href="../../../s/p/a/Sparteine.html" title="Sparteine">Sparteine</a></td>
</tr>
<tr>
<th style="">class Ib</th>
<td style="" colspan="1"><a href="../../../a/p/r/Aprindine.html" title="Aprindine">Aprindine</a>, <a href="../../../l/i/d/Lidocaine.html" title="Lidocaine">Lidocaine</a>, <a href="../../../m/e/x/Mexiletine.html" title="Mexiletine">Mexiletine</a>, <a href="../../../t/o/c/Tocainide.html" title="Tocainide">Tocainide</a></td>
</tr>
<tr>
<th style="">class Ic</th>
<td style="" colspan="1"><a href="../../../e/n/c/Encainide.html" title="Encainide">Encainide</a>, <a href="../../../f/l/e/Flecainide.html" title="Flecainide">Flecainide</a>, <a href="../../../l/o/r/Lorcainide.html" title="Lorcainide">Lorcainide</a>, <a href="../../../m/o/r/Moricizine.html" title="Moricizine">Moricizine</a>, <a href="../../../p/r/o/Propafenone.html" title="Propafenone">Propafenone</a></td>
</tr>
<tr>
<th style="">class II</th>
<td style="" colspan="1"><a href="../../../p/r/o/Propranolol.html" title="Propranolol">Propranolol</a>, <a href="../../../m/e/t/Metoprolol.html" title="Metoprolol">Metoprolol</a>, <a href="../../../n/a/d/Nadolol.html" title="Nadolol">Nadolol</a>, <a href="../../../a/t/e/Atenolol.html" title="Atenolol">Atenolol</a>, <a href="../../../a/c/e/Acebutolol.html" title="Acebutolol">Acebutolol</a>, <a href="../../../p/i/n/Pindolol.html" title="Pindolol">Pindolol</a><br />
<i>see <a href="../../../b/e/t/Beta_blockers.html" title="Beta blockers">Beta blockers</a> (<a href="../../../a/t/c/ATC_code_C07_0a08.html" title="ATC code C07">C07</a>)</i></td>
</tr>
<tr>
<th style="">class III</th>
<td style="" colspan="1"><strong class="selflink">Amiodarone</strong>, <a href="../../../b/r/e/Bretylium.html" title="Bretylium">Bretylium tosylate</a>, <a href="../../../b/u/n/Bunaftine.html" title="Bunaftine">Bunaftine</a>, <a href="../../../d/o/f/Dofetilide.html" title="Dofetilide">Dofetilide</a>, <a href="../../../i/b/u/Ibutilide.html" title="Ibutilide">Ibutilide</a>, <a href="../../../s/o/t/Sotalol.html" title="Sotalol">Sotalol</a></td>
</tr>
<tr>
<th style="">class IV</th>
<td style="" colspan="1"><a href="../../../v/e/r/Verapamil.html" title="Verapamil">Verapamil</a>, <a href="../../../d/i/l/Diltiazem.html" title="Diltiazem">Diltiazem</a><br />
<i>see <a href="../../../c/a/l/Calcium_channel_blocker.html" title="Calcium channel blocker">Calcium channel blockers</a> (<a href="../../../a/t/c/ATC_code_C08_d3ef.html" title="ATC code C08">C08</a>)</i></td>
</tr>
<tr>
<th style="">class V</th>
<td style="" colspan="1"><a href="../../../a/d/e/Adenosine.html" title="Adenosine">Adenosine</a>, <a href="../../../a/t/r/Atropine.html" title="Atropine">Atropine</a>, <a href="../../../d/i/g/Digoxin.html" title="Digoxin">Digoxin</a></td>
</tr>
</table>

<!-- 
Pre-expand include size: 37358 bytes
Post-expand include size: 13993 bytes
Template argument size: 4080 bytes
Maximum: 2048000 bytes
-->
<div class="printfooter">
Retrieved from "<a href="http://en.wikipedia.org../../../a/m/i/Amiodarone.html">http://en.wikipedia.org../../../a/m/i/Amiodarone.html</a>"</div>
	    <div id="catlinks"><p class='catlinks'><a href="../../../c/a/t/Special%7ECategories_101d.html" title="Special:Categories">Categories</a>: <span dir='ltr'><a href="../../../a/m/i/Category%7EAmines_095d.html" title="Category:Amines">Amines</a></span> | <span dir='ltr'><a href="../../../a/n/t/Category%7EAntiarrhythmic_agents_8bd5.html" title="Category:Antiarrhythmic agents">Antiarrhythmic agents</a></span> | <span dir='ltr'><a href="../../../a/r/o/Category%7EAromatic_compounds_f5ad.html" title="Category:Aromatic compounds">Aromatic compounds</a></span> | <span dir='ltr'><a href="../../../e/t/h/Category%7EEthers_08b2.html" title="Category:Ethers">Ethers</a></span> | <span dir='ltr'><a href="../../../h/e/t/Category%7EHeterocyclic_compounds_1c27.html" title="Category:Heterocyclic compounds">Heterocyclic compounds</a></span> | <span dir='ltr'><a href="../../../k/e/t/Category%7EKetones_c01f.html" title="Category:Ketones">Ketones</a></span></p></div>	    <!-- end content -->
	    <div class="visualClear"></div>
	  </div>
	</div>
      </div>
      <div id="column-one">
	<div id="p-cactions" class="portlet">
	  <h5>Views</h5>
	  <ul>
	    <li id="ca-nstab-main"
	       class="selected"	       ><a href="../../../a/m/i/Amiodarone.html">Article</a></li><li id="ca-talk"
	       	       ><a href="../../../a/m/i/Talk%7EAmiodarone_6370.html">Discussion</a></li><li id="ca-current"
	       	       ><a href="http://en.wikipedia.org/wiki/Amiodarone">Current revision</a></li>	  </ul>
	</div>
	<div class="portlet" id="p-logo">
	  <a style="background-image: url(../../../images/wiki-en.png);"
	    href="../../../index.html"
	    title="Main Page"></a>
	</div>
	<script type="text/javascript"> if (window.isMSIE55) fixalpha(); </script>
		<div class='portlet' id='p-navigation'>
	  <h5>Navigation</h5>
	  <div class='pBody'>
	    <ul>
	    	      <li id="n-Main-page"><a href="../../../index.html">Main page</a></li>
	     	      <li id="n-Contents"><a href="../../../c/o/n/Wikipedia%7EContents_3181.html">Contents</a></li>
	     	      <li id="n-Featured-content"><a href="../../../f/e/a/Wikipedia%7EFeatured_content_24ba.html">Featured content</a></li>
	     	      <li id="n-currentevents"><a href="../../../c/u/r/Portal%7ECurrent_events_bb60.html">Current events</a></li>
	     	    </ul>
	  </div>
	</div>
		<div class='portlet' id='p-interaction'>
	  <h5>interaction</h5>
	  <div class='pBody'>
	    <ul>
	    	      <li id="n-About-Wikipedia"><a href="../../../a/b/o/Wikipedia%7EAbout_8d82.html">About Wikipedia</a></li>
	     	      <li id="n-portal"><a href="../../../c/o/m/Wikipedia%7ECommunity_Portal_6a3c.html">Community portal</a></li>
	     	      <li id="n-contact"><a href="../../../c/o/n/Wikipedia%7EContact_us_afd6.html">Contact us</a></li>
	     	      <li id="n-sitesupport"><a href="http://wikimediafoundation.org/wiki/Fundraising">Make a donation</a></li>
	     	      <li id="n-help"><a href="../../../c/o/n/Help%7EContents_22de.html">Help</a></li>
	     	    </ul>
	  </div>
	</div>
		<div id="p-search" class="portlet">
	  <h5><label for="searchInput">Search</label></h5>
	  <div id="searchBody" class="pBody">
	    <form action="javascript:goToStatic(3)" id="searchform"><div>
	      <input id="searchInput" name="search" type="text"
	        accesskey="f" value="" />
	      <input type='submit' name="go" class="searchButton" id="searchGoButton"
	        value="Go" />
	    </div></form>
	  </div>
	</div>
	<div id="p-lang" class="portlet">
	  <h5>In other languages</h5>
	  <div class="pBody">
	    <ul>
	      	      <li>
	      <a href="../../../../de/a/m/i/Amiodaron.html">Deutsch</a>
	      </li>
	      	      <li>
	      <a href="../../../../es/a/m/i/Amiodarona.html">EspaÃ±ol</a>
	      </li>
	      	      <li>
	      <a href="../../../../fr/a/m/i/Amiodarone.html">FranÃ§ais</a>
	      </li>
	      	      <li>
	      <a href="../../../../he/%D7%90/%D7%9E/%D7%99/%D7%90%D7%9E%D7%99%D7%95%D7%93%D7%90%D7%A8%D7%95%D7%9F.html">×¢×‘×¨×™×ª</a>
	      </li>
	      	      <li>
	      <a href="../../../../pl/a/m/i/Amiodaron.html">Polski</a>
	      </li>
	      	      <li>
	      <a href="../../../../pt/a/m/i/Amiodarona.html">PortuguÃªs</a>
	      </li>
	      	    </ul>
	  </div>
	</div>
	      </div><!-- end of the left (by default at least) column -->
      <div class="visualClear"></div>
      <div id="footer">
    <div id="f-poweredbyico"><a href="http://www.mediawiki.org/"><img src="../../../skins/common/images/poweredby_mediawiki_88x31.png" alt="Powered by MediaWiki" /></a></div>	<div id="f-copyrightico"><a href="http://wikimediafoundation.org/"><img src="../../../images/wikimedia-button.png" border="0" alt="Wikimedia Foundation"/></a></div>	<ul id="f-list">
	  	  	  <li id="f-credits">This page was last modified 13:02, 27 March 2007 by Anonymous user(s) of Wikipedia. Based on work by Wikipedia user(s) <a href="../../../f/l/a/User%7EFlaBot_747f.html" title="User:FlaBot">FlaBot</a>, <a href="../../../s/e/l/User%7ESelket_adc6.html" title="User:Selket">Selket</a>, Jonnyjwalton, <a href="../../../g/a/i/User%7EGaius_Cornelius_c35a.html" title="User:Gaius Cornelius">Gaius Cornelius</a>, <a href="../../../m/e/l/User%7EMellery_d65a.html" title="User:Mellery">Mellery</a>, <a href="../../../h/u/1/User%7EHu12_d0ca.html" title="User:Hu12">Hu12</a>, <a href="../../../j/f/d/User%7EJfdwolff_9ea6.html" title="User:Jfdwolff">Jfdwolff</a>, <a href="../../../d/a/v/User%7EDavidruben_76a6.html" title="User:Davidruben">Davidruben</a>, <a href="../../../a/p/p/User%7EAppraiser_5597.html" title="User:Appraiser">Appraiser</a>, <a href="../../../a/r/c/User%7EArcadian_5c4b.html" title="User:Arcadian">Arcadian</a>, <a href="../../../b/w/h/User%7EBwhack_e9d6.html" title="User:Bwhack">Bwhack</a>, <a href="../../../k/n/o/User%7EKnowledgeOfSelf_7104.html" title="User:KnowledgeOfSelf">KnowledgeOfSelf</a>, Jlabarbera, SimonWaters, <a href="../../../d/r/e/User%7EDreadlocke_8280.html" title="User:Dreadlocke">Dreadlocke</a>, <a href="../../../e/p/o/User%7EEpolk_d8a6.html" title="User:Epolk">Epolk</a>, <a href="../../../b/e/e/User%7EBeetstra_df14.html" title="User:Beetstra">Beetstra</a>, <a href="../../../s/m/a/User%7ESmackBot_cc7a.html" title="User:SmackBot">SmackBot</a>, Optweb, <a href="../../../d/o/n/User%7EDonaldal_0934.html" title="User:Donaldal">Donaldal</a>, <a href="../../../b/i/g/User%7EBignoter_5b59.html" title="User:Bignoter">Bignoter</a>, <a href="../../../b/l/u/User%7EBluebot_e595.html" title="User:Bluebot">Bluebot</a>, <a href="../../../w/i/k/User%7EWikipedia_brown_aa79.html" title="User:Wikipedia brown">Wikipedia brown</a>, <a href="../../../r/o/b/User%7ERobyWayne_5f41.html" title="User:RobyWayne">RobyWayne</a>, Vochee, <a href="../../../l/e/o/User%7ELeonardoRob0t_c34e.html" title="User:LeonardoRob0t">LeonardoRob0t</a>, <a href="../../../t/s/a/User%7ETsai_the_wanderer_63af.html" title="User:Tsai the wanderer">Tsai the wanderer</a>, <a href="../../../s/a/l/User%7ESalvadorjo_220f.html" title="User:Salvadorjo">Salvadorjo</a>, <a href="../../../c/a/c/User%7ECacycle_6f2f.html" title="User:Cacycle">Cacycle</a>, Faderrattnerb, <a href="../../../t/h/e/User%7ETheodore_Kloba_cbef.html" title="User:Theodore Kloba">Theodore Kloba</a>, <a href="../../../b/r/i/User%7EBrian_Sayrs_0284.html" title="User:Brian Sayrs">Brian Sayrs</a>, <a href="../../../n/i/c/User%7ENickj_5f86.html" title="User:Nickj">Nickj</a>, <a href="../../../k/s/h/User%7EKsheka_e2cf.html" title="User:Ksheka">Ksheka</a>, <a href="../../../m/y/k/User%7EMykhal_d2ab.html" title="User:Mykhal">Mykhal</a>, <a href="../../../g/e/n/User%7EGentgeen_2e43.html" title="User:Gentgeen">Gentgeen</a>, <a href="../../../d/c/o/User%7EDcoetzeeBot_3e52.html" title="User:DcoetzeeBot">DcoetzeeBot</a>, <a href="../../../d/i/b/User%7EDiberri_3d04.html" title="User:Diberri">Diberri</a>, <a href="../../../p/f/h/User%7EPFHLai_0319.html" title="User:PFHLai">PFHLai</a>, <a href="../../../e/e/q/User%7EEequor_b13d.html" title="User:Eequor">Eequor</a> and <a href="../../../m/i/c/User%7EMichael_Hardy_e932.html" title="User:Michael Hardy">Michael Hardy</a>.</li>	  <li id="f-copyright">All text is available under the terms of the <a class='internal' href="../../../t/e/x/Wikipedia%7EText_of_the_GNU_Free_Documentation_License_702a.html" title="Wikipedia:Text of the GNU Free Documentation License">GNU Free Documentation License</a>. (See <b><a class='internal' href="../../../c/o/p/Wikipedia%7ECopyrights_92c4.html" title="Wikipedia:Copyrights">Copyrights</a></b> for details.) <br /> Wikipedia&reg; is a registered trademark of the <a href="http://www.wikimediafoundation.org">Wikimedia Foundation, Inc</a>., a US-registered <a class='internal' href="../../../5/0/1/501%28c%29.html#501.28c.29.283.29" title="501(c)(3)">501(c)(3)</a> <a href="http://wikimediafoundation.org/wiki/Deductibility_of_donations">tax-deductible</a> <a class='internal' href="../../../n/o/n/Non-profit_organization.html" title="Non-profit organization">nonprofit</a> <a href="../../../c/h/a/Charitable_organization.html" title="Charitable organization">charity</a>.<br /></li>	  <li id="f-about"><a href="../../../a/b/o/Wikipedia%7EAbout_8d82.html" title="Wikipedia:About">About Wikipedia</a></li>	  <li id="f-disclaimer"><a href="../../../g/e/n/Wikipedia%7EGeneral_disclaimer_3e44.html" title="Wikipedia:General disclaimer">Disclaimers</a></li>	  	</ul>
      </div>
    </div>
  </body>
</html>
